It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

Antibodies are well established in mainstream clinical practice and present an exciting area
for collaborative research and development in industry and academia alike. In this review …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Correspondence to: Alain Beck; Email: alain. beck@ pierre-fabre. com Submitted: 01/11/10;
Accepted: 01/11/11 DOI: 10.4161/mabs. 3.2. 14785 in a sometimes confusing way. 4 To …

Antibodies can have exquisite specificity of target recognition and thus generate highly
selective outcomes following their systemic administration. While antibodies can have high …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical
industry. There are currently 18 monoclonal antibodies in the market that have been …

Biosimilar agents are approximate copies of branded biologic therapies. Since the first
biosimilar was authorized in the European Union in 2006, fifteen additional agents have …

Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …